Bank of New York Mellon Portfolio holdings
Bank of New York Mellon (BNY Mellon), tracing its origins to 1784 when Alexander Hamilton founded the Bank of New York, is a global financial institution headquartered in New York City, specializing in asset servicing, custody banking, and investment management. As one of the world’s largest custodian banks, it safeguards trillions in assets for institutions like pension funds, mutual funds, and governments, while its investment arm manages billions through subsidiaries like Mellon Investments and Dreyfus. Known for its role as a financial infrastructure backbone, BNY Mellon also provides treasury services, wealth management, and market analytics, blending a rich historical legacy with modern fintech innovations. The 2007 merger of Bank of New York and Mellon Financial solidified its position as a leader in global finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Idexx Laboratories
IDXX
|
+$423M |
| 2 |
Mettler-Toledo International
MTD
|
+$421M |
| 3 |
Capital One
COF
|
+$383M |
| 4 |
L3Harris
LHX
|
+$325M |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$262M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$1.83B |
| 2 |
Microsoft
MSFT
|
+$1.62B |
| 3 |
Apple
AAPL
|
+$1.56B |
| 4 |
NVIDIA
NVDA
|
+$1.36B |
| 5 |
Costco
COST
|
+$731M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.97% |
| 2 | Financials | 13.28% |
| 3 | Healthcare | 9.87% |
| 4 | Consumer Discretionary | 9.75% |
| 5 | Industrials | 9.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4001
Lineage Cell Therapeutics
LCTX
$268M
| $16.1K | ﹤0.01% |
17,795
-320,032
| -95% | -$190K |
|
4002
Neumora Therapeutics
NMRA
$324M
| $14.5K | ﹤0.01% |
19,836
-208,019
| -91% | -$158K |
|
|
PRPH
4003
DELISTED
ProPhase Labs
PRPH
| $14.5K | ﹤0.01% |
3,705
| – | – |
|
4004
Rekor Systems
REKR
$98M
| $13.7K | ﹤0.01% |
11,819
-160,064
| -93% | -$168K |
|
4005
SES AI
SES
$215M
| $12.5K | ﹤0.01% |
14,031
-320,322
| -96% | -$269K |
|
4006
Wheels Up
UP
$191M
| $12.1K | ﹤0.01% |
564
-9,081
| -94% | -$223K |
|
|
SGMO
4007
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $12.1K | ﹤0.01% |
22,267
| – | – |
|
|
FPAY
4008
DELISTED
FlexShopper
FPAY
| $12K | ﹤0.01% |
+10,001
| New | +$12.7K |
|
|
ORGN
4009
DELISTED
Origin Materials
ORGN
| $9.96K | ﹤0.01% |
687
+7
| +1% | +$118 |
|
4010
Atossa Therapeutics
ATOS
$24.5M
| $9.25K | ﹤0.01% |
743
-18,572
| -96% | -$222K |
|
4011
Westwater Resources
WWR
$76.1M
| $7.91K | ﹤0.01% |
13,153
| – | – |
|
|
CNF
4012
CNFinance Holdings
CNF
$41.1M
| $7.18K | ﹤0.01% |
1,105
| – | – |
|
|
VXRT
4013
DELISTED
Vaxart
VXRT
| $6.59K | ﹤0.01% |
14,591
+1
| +0% | – |
|
4014
ProKidney
PROK
$293M
| $6.25K | ﹤0.01% |
10,549
-229,124
| -96% | -$178K |
|
|
OPI
4015
DELISTED
Office Properties Income Trust
OPI
| $4.89K | ﹤0.01% |
+19,815
| New | +$5.57K |
|
4016
Biodesix
BDSX
$254M
| $3.95K | ﹤0.01% |
700
| – | – |
|
|
LNAI
4017
Lunai Bioworks
LNAI
$10.5M
| $3.47K | ﹤0.01% |
150
-2,853
| -95% | -$79.7K |
|
4018
Acumen Pharmaceuticals
ABOS
$177M
| – | – |
-90,258
| Closed | -$99.3K |
|
4019
Achieve Life Sciences
ACHV
$737M
| – | – |
-80,357
| Closed | -$215K |
|
4020
Acrivon Therapeutics
ACRV
$78.8M
| – | – |
-27,635
| Closed | -$56.1K |
|
|
ADVM
4021
DELISTED
Adverum Biotechnologies
ADVM
| – | – |
-49,324
| Closed | -$216K |
|
|
AGEN
4022
Agenus
AGEN
$311M
| – | – |
-54,727
| Closed | -$82.4K |
|
|
AKYA
4023
DELISTED
Akoya BioSciences
AKYA
| – | – |
-45,220
| Closed | -$62.9K |
|
4024
ALX Oncology
ALXO
$272M
| – | – |
-89,199
| Closed | -$55.6K |
|
4025
Aemetis
AMTX
$127M
| – | – |
-88,707
| Closed | -$154K |
|
Similar funds
Bank of New York Mellon's Q2 2025 Portfolio in Review
As of Q2 2025, Bank of New York Mellon held 4,353 positions worth $529B, up 4.8% from $505B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Bank of New York Mellon withdrew a net $22.6B in Q2 2025, closing 217 positions and reducing 1,932 holdings. Its most notable exit was Discover Financial Services, an estimated $274M position sold in full.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 25% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Bank of New York Mellon opened a new position in JPMorgan Hedged Equity Laddered Overlay ETF worth $93.7M.
- Bank of New York Mellon's largest Q2 2025 buy was JPMorgan Hedged Equity Laddered Overlay ETF: 1,498,016 shares worth $93.7M.
- Bank of New York Mellon added most to Idexx Laboratories in Q2 2025, an estimated $423M increase.
- Bank of New York Mellon's biggest Q2 2025 reduction was Alphabet (Google) Class C, cutting an estimated $1.83B.
- Bank of New York Mellon fully exited Discover Financial Services in Q2 2025, selling an estimated $274M.
- Bank of New York Mellon's ten largest holdings make up 25% of its $529B portfolio in Q2 2025.
- Bank of New York Mellon opened 243 new positions and closed 217 in Q2 2025.
- Bank of New York Mellon's portfolio value rose 4.8% quarter-over-quarter to $529B.
Based on Bank of New York Mellon's 13F filing for Q2 2025, filed 5 Aug 2025.